The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo
about
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in miceHDAC inhibitors as anti-inflammatory agentsThe many roles of histone deacetylases in development and physiology: implications for disease and therapyHDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesHistone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseasesHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyHDAC inhibitors and immunotherapy; a double edged sword?Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammationHistone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophagesGenetics and epigenetics of rheumatoid arthritisPiceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK SignalingInsecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprinaHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity.Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NADHistone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19bTherapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and UnRegulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestinsIncreased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritisHelper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes.Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production.Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivoHistone deacetylase inhibitors for treating a spectrum of diseases not related to cancerEffects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes.Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).HDAC inhibition and graft versus host diseaseThe therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosisThe oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.Augmenting antitumor immune responses with epigenetic modifying agents.Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model.Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8.TNF-α blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis.Potential non-oncological applications of histone deacetylase inhibitors.Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression.
P2860
Q24288997-D678AA68-BEA9-4F5E-865A-F83D1CE65FF3Q24564962-CC97A615-109B-4CB1-A251-82D7A56AD141Q24628821-B11AD678-9D5D-4C09-A642-C3FD00BCE3C9Q26739120-25FCB03A-8501-4BF0-8216-EB521E8F41E6Q26768497-9C0C1A71-F8DE-4144-B2A8-D4341B20D1B8Q26783032-36F1F0EC-E66F-45F5-BD24-05AE81A0B136Q26853102-E118E2DB-7338-42EE-BF06-A868408482AAQ28076052-B31F4A71-91E1-4726-943D-0752964885F5Q28294510-FD81165E-DE29-46BB-9287-65BE9A53CC9CQ28534348-11798363-5C00-429A-9D9D-3CBE731192ABQ28554628-1D0DEA8C-CB51-401B-8C7F-0EC81123CC29Q28818731-3ECEA938-DD0C-4568-B4A7-CD628331E05DQ30251920-32F3635C-9490-414B-9BC0-393D7F8E3C52Q30666883-37B02318-9E52-4C32-BE72-E50CDF91909FQ33336612-6CA208A9-8FAF-49F2-8990-6BB2CF3901FAQ33613257-668F874D-68FE-452D-8EAA-983AA871969CQ33632244-4D0BEAE1-8923-4AF8-81D6-F5CF7B4984FDQ33869272-E06DE63F-8F22-4D6E-8BFA-888D88DC6B6FQ33998649-D8D4FCD8-38DB-4538-86CF-E9C915C99077Q34048411-6E779353-91F5-4649-A156-C2465AB48DA1Q34091848-33F22BDB-1E2B-48C6-B215-CF742FED4BD1Q34152949-9087F292-870E-4BFE-8994-E2B4A4D254FAQ34356521-C4FEDBD1-0F87-40FA-805C-F3A66C44A2DBQ34635234-488DE81F-809E-4ADD-8559-7FFDC497BEDBQ34640790-355ABB7B-2887-4198-9AE9-1272FEFA03E6Q34739990-27433F5F-1401-4F16-86D9-2EF4337BFD1BQ34988095-FD20ED71-1A0C-4FE6-909A-C57EC2CCB926Q35002986-FEA1175E-561C-42FF-AA3A-4D980CA819BFQ35016934-C5EC16FE-A208-45B3-B2C2-3213B559A3CDQ35016951-695B6C8F-F1E2-479B-8407-ECDEBB8B793EQ35016969-39D1D541-DEE0-4351-AF46-FDF715524B3EQ35016985-A2E6ED23-17C1-415F-A3E0-F9522A621F5BQ35016997-3834DA33-9B88-4AFC-9C46-ECD5127B3B80Q35017018-689CE9E9-F979-47C7-8C61-84F899A88229Q35048054-E6BE2CC4-6FBA-4998-912F-13461931BCA6Q35058878-790E8D12-12CD-4372-B53B-351D64A0BD13Q35134756-ACBD498E-85DC-4D58-96E6-70EB3139004FQ35220914-52F01F0F-701D-4B72-A6B4-C1FCCE1D7CE5Q35485587-FF2E7AA3-4900-42D4-BE08-EECE8A34033EQ35599579-0E062364-E099-4266-9147-42C04DF424D5
P2860
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The histone deacetylase inhibi ...... systemic inflammation in vivo
@ast
The histone deacetylase inhibi ...... systemic inflammation in vivo
@en
The histone deacetylase inhibi ...... systemic inflammation in vivo
@nl
type
label
The histone deacetylase inhibi ...... systemic inflammation in vivo
@ast
The histone deacetylase inhibi ...... systemic inflammation in vivo
@en
The histone deacetylase inhibi ...... systemic inflammation in vivo
@nl
prefLabel
The histone deacetylase inhibi ...... systemic inflammation in vivo
@ast
The histone deacetylase inhibi ...... systemic inflammation in vivo
@en
The histone deacetylase inhibi ...... systemic inflammation in vivo
@nl
P2093
P2860
P1433
P1476
The histone deacetylase inhibi ...... systemic inflammation in vivo
@en
P2093
Britta Siegmund
Daniela Modena
Eli C Lewis
Flavio Leoni
Giamila Fantuzzi
Gianluca Fossati
Giulia Porro
Jae-Kwon Lee
Leonid L Reznikov
Maria Lusia Moras
P2860
P2888
P356
10.2119/2006-00005.DINARELLO
P407
P577
2005-01-01T00:00:00Z
P6179
1068964917